Figure 2. The efficiency with the different optimizations compared to the standard design. 100 % effeciency indicates no improvement compared to the standard.

Slides:



Advertisements
Similar presentations
Glycemic Control in Acutely Ill Patients Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard Medical School Senior Vice President for.
Advertisements

Background and Objectives Methods and Materials Results Conclusions References Increased computing power gives us the possibility of building more complex.
Lecture 10 Comparison and Evaluation of Alternative System Designs.
How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (
Copyright © Cengage Learning. All rights reserved. CHAPTER 11 ANALYSIS OF ALGORITHM EFFICIENCY ANALYSIS OF ALGORITHM EFFICIENCY.
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial Journal Club 09/01/11 JAMA, February 4, 2009—Vol 301, No
Insulin therapy.
Laplace transformation
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.
Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences Optimizing Dosing Strategies for Defined Therapeutic Targets Mats.
Influence of the size of the cohorts in adaptive design for nonlinear mixed effect models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic.
Results: In the presence of PD measurements, PK data provided little additional information. By a limited PD sampling the number of patients on target.
New Insulin Formulations
Toujeo® and it’s Place in Therapy
Enteric-coated alendronate sodium solid lipid nanoparticles; a novel formula to overcome barriers for the treatment of osteoporosis By Funded Project.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
Results: Accuracy and precision expressed as MPE and RMSE was better for the proposed model compared to the Sam and Staatz models. Graphical diagnostics.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Adaptive randomization
Biostatistics in Practice Peter D. Christenson Biostatistician Session 6: Case Study.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
ABSTRACT Hyperglycaemia is prevalent in critical care, and tight control reduces mortality. Targeted glycaemic control can be achieved by frequent fitting.
Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.
Multiple dosing: intravenous bolus administration
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Continuous intravenous infusion (one-compartment model)
BIOPHARMACEUTICS.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
The Super Bolus And The Projected BG Alert New Insulin Pump Ideas To Improve Glucose Levels, Avoid Hypoglycemia And Speed Correction Of Hyperglycemia John.
1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.
1 of 48 The EPA 7-Step DQO Process Step 6 - Specify Error Tolerances 3:00 PM - 3:30 PM (30 minutes) Presenter: Sebastian Tindall Day 2 DQO Training Course.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Paper Writing and Abstract Writing Prof. Peih-ying Lu School of Medicine Kaohsiung Medical University.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Effect of Four Different Meal Types on the Population Pharmacokinetics of Single Dose of Rifapentine in Healthy Male Volunteers Simbarashe P. Zvada 1,
Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences Uppsala University Sweden Sequential versus Simultaneous.
1 INTRODUCTION Nearly 25% of diabetes patients use insulin Many practitioners: –Are uncomfortable with insulin dosing –Base dosing decisions on empiric.
Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose Diabetes Division and the Clinical.
MULTIPLE DOSAGE REGIMEN
Pharmacometrics research group Department of Pharmaceutical Biosciences Uppsala University Approximations of the population Fisher information matrix-
Sarah M. Coors, DO1, PGY-6, Joseph L. Hagan, ScD1, Joshua J
Nallasamy K, Jayashree M, Singhi S, Bansal A
Temocillin pharmacokinetics in healthy volunteers
Safety and efficacy of insulin guideline for controlling perioperative hyperglycemia Marwa Amer PharmD Candidate1, Mark Shelly MD2, Dianne Lee PharmD Candidate1,
GLUCOSE TOLERANCE TEST (GTT)
Metformin Use in Chronic Kidney Disease
Evaluation of a plasma Insulin Model for Glycaemic Control in Intensive Care Jennifer Dickson, Felicity Thomas, Chris Pretty, Kent Stewart, Geoffrey Shaw,
The MDRD Study.
Components of a CGM record over a 3
Technosphere® Inhaled Human Insulin has a More Rapid Onset of Action Than Subcutaneous Insulins - Meta Analysis of Clamp data From Three Clinical Studies.
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Background and Objectives
Volume 25, Issue 22, Pages (November 2015)
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Risk ratios 12/6/ : Risk Ratios 12/6/2018 Risk ratios StatPrimer.
Pramlintide Synthetic analog of the β-cell hormone amylin
PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
A whole body model for both glucose and fatty acid metabolism
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Volume kinetics of glucose solutions given by intravenous infusion†
One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.
Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.
Intracerebroventricular (ICV) insulin infusion increases TG secretion.
Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.
Fig. 5 In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig.
(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.
Grace K. Mahoney, MS, Henry J. Henk, PhD, Rozalina G. McCoy, MD, MS 
Presentation transcript:

Figure 2. The efficiency with the different optimizations compared to the standard design. 100 % effeciency indicates no improvement compared to the standard design. Optimal design of the intravenous glucose tolerance test (IVGTT) in type 2 diabetic patients Background and Objective Intravenous glucose provocations are very informative for studying the glucose-insulin system. The standard frequently sampled IVGTT design contains approximately 30 blood samples of glucose, insulin and sometimes also labeled glucose during 4 hours following an intravenous bolus dose of glucose. In the insulin modified IVGTT, a 5-minute insulin infusion is given at 20 minutes. Optimal experimental design is a model based methodology that can be used to increase the efficiency of clinical trials by optimizing the sampling schedule or other design parameters, e.g. dose. As a suitable model for describing the IVGTT is available it was used for optimization of study design with respect to precision of parameter estimates. The objective of this study was to evaluate the possibilities of an improved study design of the insulin modified IVGTT in type 2 diabetic patients. Figure 1. Model of glucose and insulin regulation in type 2 diabetic patients developed by Silber et al. 1 The model contains sub-models for glucose, insulin and labeled glucose (not shown) as well as control mechanisms for glucose uptake and insulin secretion. Results The results show that the design of the insulin modified IVGTT can be substantially improved by the use of an optimal design compared to the standard design, see table 1 and figure 2. Despite the comparably low number of samples included the predicted uncertainty of parameter estimates was low in all tested cases. The single largest improvement of the design was given when the insulin dose was modified, giving an increased efficiency of 304% compared to the standard design. With that design it is possible to reduce the number of individuals in a study to 1/3 compared to when the basic design is used. Optimizing on the insulin infusion resulted in only minor improvements. When hot glucose was excluded the efficiency of the standard design was only 21% compared to the standard design, indicating that hot glucose contains much information. Optimizing on sampling times resulted in modest improvement of efficiency indicating that already 10 samples provide an informative design and that ”the room for improvement” is limited. When both glucose and insulin doses were optimized simulatenously this resulted in high doses of both despite the boundaries on glucose concentration. Methods A previously published model developed for glucose and insulin regulation in type 2 diabetic patients was implemented in the optimal design software PopED 1,2 (see figure 1). The standard experimental design was a 0.3 g/kg intravenous glucose dose at time 0 followed by an insulin infusion of 50 mU/kg at 20 minutes. In order to decrease run times the number of samples was reduced to 10 (0, 2, 10, 15, 30, 45, 70, 100, 150, 240 minutes). Several aspects of the study design of the insulin modified IVGTT were evaluated including; (1) glucose dose, (2) insulin dose (start and stop time and total insulin dose), (3) combination of glucose and insulin dose, (4) sampling times of a reduced sampling schedule, and (5) exclusion of labeled glucose. Constraints were incorporated to avoid prolonged hyper- and/or hypoglycemia. The lower constraint was set to a glucose concentration of 54mg/dL during the entire experiment and the upper constraint was set to 360 mg/dL after 30 minutes (approximately twice the baseline glucose concentration). The constraints on glucose concentrations were incorporated in order to restrict the search space with the lower boundary restricting the maximum insulin dose and the upper boundary the maximum glucose dose allowed. Efficiency was calculated as a measure of the improvement with an optimal design compared to the basic design according to equation 1. The determinant of the Fisher Information Matrix (FIM) of the optimal design was compared to the FIM of the basic design correcting for the number of parameters in the model. Equation 1 Conclusion We conclude that improvement can be made to the design of the insulin modified IVGTT. Also when the number of samples is reduced parameters are predicted to be estimated with a high certainty. This illustrates how complex provocation experiments can be improved by sequential modeling and optimal design. Authors: Hanna E Silber*, Joakim Nyberg, Andrew Hooker, Mats O Karlsson Institution: Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden References: 1. Silber H E, Jauslin P M, Frey N, Gieschke R, Simonsson U S H, and Karlsson M O. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol 2007; 47: Foracchia M, Hooker A, Vicini P, and Ruggeri A. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74: OptimizationStandard designOptimal design Insulin dose50 mU/kg264 mU/kg Insulin start of infusion20 min43.3 min Insulin infusion length5 min9.1 min Insulin dose, start and stopstart time=20 min stop time=25 min dose = 50 mU/kg start time=33.6 min stop time=47.5 min dose = mU/kg Glucose dose0.3 mg/kg0.81 mg/kg Glucose + insulin doseglucose=0.3 mg/kg, insulin=50 mU/kg glucose=5.4 mg/kg, insulin=442.4 mU/kg Sampling times0, 2, 10, 15, 30, 45, 70, 100, 150, 240 minutes 2.1, 19.9, 19.9, 24, 43.2, 48, 81.6, 112.1, 240, 240 minutes. Table 1. Results of optimization